NASDAQ:NK - Nasdaq -
32.49
+4.21 (+14.89%)
The current stock price of NK is 32.49 null. In the past month the price increased by 21.23%. In the past year, price increased by 951.46%.
NantKwest, Inc. is a clinical-stage immunotherapy company. The Company's product candidates include aNK, haNK and taNK for the treatment of cancers, infectious and inflammatory diseases. It is focused on harnessing the power of the innate immune system by using the natural killer cell. NantKwest, Inc. is headquartered in Cardiff-by-the-Sea, California.
Nantkwest Inc CS
3530 JOHN HOPKINS COURT
SAN DIEGO CA 92121
CEO: Richard Adcock
Phone: 858-633-0300
The current stock price of NK is 32.49 null. The price increased by 14.89% in the last trading session.
The exchange symbol of Nantkwest Inc CS is NK and it is listed on the Nasdaq exchange.
NK stock is listed on the Nasdaq exchange.
Nantkwest Inc CS (NK) has a market capitalization of 3.55B null. This makes NK a Mid Cap stock.
Nantkwest Inc CS (NK) has a support level at 26.74. Check the full technical report for a detailed analysis of NK support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
NK does not pay a dividend.
Nantkwest Inc CS (NK) will report earnings on 2022-03-03, after the market close.
Nantkwest Inc CS (NK) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.71).
ChartMill assigns a technical rating of 9 / 10 to NK. When comparing the yearly performance of all stocks, NK is one of the better performing stocks in the market, outperforming 98.43% of all stocks.
ChartMill assigns a fundamental rating of 3 / 10 to NK. The financial health of NK is average, but there are quite some concerns on its profitability.
Over the last trailing twelve months NK reported a non-GAAP Earnings per Share(EPS) of -0.7100000000000001. The EPS increased by 21.98% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | -83227.93% | ||
ROA | -60.84% | ||
ROE | N/A | ||
Debt/Equity | 0.08 |
ChartMill assigns a Buy % Consensus number of 100% to NK. The Buy consensus is the average rating of analysts ratings from 1 analysts.